Abstracts tagged "osteoporosis"

Abstract Number: 2217 • 2019 ACR/ARP Annual Meeting
DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids
Sima Terebelo¹, Madina Abduraimova ¹, Latoya Freeman-Beman ¹, Naureen Kabani ², Joshy Pathiparampil ¹, Olga Dvorkina ² and Ellen M Ginzler ³, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, ³State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Osteoporosis (OP) is a problem in the aging population. Patients with autoimmune disease are at increased risk for OP given their history of steroid…
Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Erik Eriksen¹, Roland Chapurlat ², Rogely Boyce ³, Jacques Brown ⁴, Stéphane Horlait ⁵, Cesar Libanati ⁶, Yifei Shi ³, Rachel Wagman ³ and Pascale Chavassieux ², ¹Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway, ²INSERM UMR 1033, Université de Lyon, Lyon, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ⁵Amgen Inc., Boulogne Billancourt, France, ⁶UCB Pharma, Brussels, Belgium
Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 1877 • 2019 ACR/ARP Annual Meeting
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Jacques Brown¹, Arkadi Chines ², Roland Chapurlat ³, Joseph Foldes ⁴, Xavier Nogues ⁵, Roberto Civitelli ⁶, Tobias De Villiers ⁷, Fabio Massari ⁸, Cristiano A. Zerbini ⁹, Wenjing Yang ², Chris Recknor ¹⁰ and Cesar Libanati ¹¹, ¹CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³INSERM UMR 1033, Université de Lyon, Lyon, France, ⁴Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁵IMIM Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ⁹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹⁰United Osteoporosis Centers, Gainesville, GA, ¹¹UCB Pharma, Brussels, Belgium
Background/Purpose: Recent evidence suggests BMD achieved during treatment is a reliable surrogate for fracture risk reduction (Bouxsein JBMR 2019). Romosozumab (Romo) is a bone-forming agent…
Abstract Number: 2220 • 2019 ACR/ARP Annual Meeting
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
Nancy Lane¹, Richard Weiss ², Bruce Mitlak ³, Yamei Wang ⁴, Guillermo Valenzuela ⁵ and Chad Deal ⁶, ¹University of California at Davis Medical Center, Sacramento, CA, ²Radius Health, Inc, Waltham, ³Radius Health, Inc, Waltham, MA, ⁴Radius Health, Inc, Waltham, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Osteoporosis (OP) and osteoarthritis (OA) are often comorbid conditions in the elderly, with prevalence of OP in patients with OA reported as high as…
Abstract Number: 1929 • 2019 ACR/ARP Annual Meeting
Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women
Levi Jales Neto¹, Zofia Wicik ², Georgea Torres ¹, Liliam Takayama ¹, Neusa Lopes ¹, alexandre Pereira ¹ and Rosa Pereira ³, ¹University of Sao Paulo, Sao Paulo, Brazil, ²University of Sao Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: The pathogenesis of osteoporosis, a common disease with high morbidity1, comprises genetic and environmental factors2. Recent studies demonstrated that blood samples are a source…
Abstract Number: 2221 • 2019 ACR/ARP Annual Meeting
Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study
Luis Seguro ¹, Rosa Pereira ², Luciana Seguro³, Valeria Caparbo ³, Monica Avila ¹, Sandrigo Mangini ¹, Iascara Campos ¹, Fabio Gaiotto ¹, Fabiana Marcondes-Braga ¹ and Fernando Bacal ¹, ¹Instituto do Coracao (InCor), HCFMUSP, Sao Paulo, ²Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo
Background/Purpose: Data on prevention of fractures after heart transplant (HTx) are controversial in the literature. Understanding the effects of HTx on bone may guide appropriate…
Abstract Number: 2323 • 2018 ACR/ARHP Annual Meeting
Predictors of Mortality in Patients with Hip Fragility Fracture
Miguel Guerra¹, Sara Ganhão^2,3, Francisca Aguiar^2,3, Georgina Terroso², Romana Vieira¹, Diana Gonçalves⁴, Tiago Meirinhos⁵, Teresa Martins-Rocha^2,3, Ana Águeda^3,5, Raquel Ferreira^2,3, Miguel Bernardes^2,3, Carlos Vaz^2,3, Raquel Lucas⁶ and Lúcia Costa², ¹Rheumatology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, ²Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ³Faculty of Medicine, Oporto University, Oporto, Portugal, ⁴Rheumatology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ⁵Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁶Public Health Institute of Oporto University, Oporto, Portugal
Background/Purpose: In Osteoporosis, hip fractures account for significant disease burden, with increased morbi-mortality and financial load on the patient and healthcare system. This study aimed…
Abstract Number: 2326 • 2018 ACR/ARHP Annual Meeting
Outcomes One Year after Hip Fracture Repair in the Elderly: Does Social Isolation Matter?
Lisa A. Mandl¹, Serena Lian¹, Jackie Szymonifka², Kirsten Grueter³, Aidan Hadad³ and Joseph Lane³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Orthopaedic Surgery, Hospital for Special Surgery, New York, NY
Background/Purpose: Hip fractures are a serious public health issue with a significant population burden, especially among those over age 65. Social isolation—how integrated a patient…
Abstract Number: 2336 • 2018 ACR/ARHP Annual Meeting
Identification of Osteoporosis As a Reason for Vertebral Fractures in Patients with Rheumatoid Arthritis and Non-Inflammatory Musculoskeletal Diseases – a Comparison between Trabecular Bone Score (TBS) and Bone Mineral Density (BMD)
Bjoern Buehring¹, Xenofon Baraliakos¹, Julian Thomas² and Jürgen Braun¹, ¹Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany
Identification of osteoporosis as a reason for vertebral fractures in patients with rheumatoid arthritis and non-inflammatory musculoskeletal diseases – A comparison between trabecular bone score…
Abstract Number: 1144 • 2018 ACR/ARHP Annual Meeting
Risk of Osteoporotic Fractures in Patients with Rheumatoid Arthritis and End Stage Renal Disease. Findings from the Usrds Database
Renee Peterkin-McCalman, Jennifer Waller, Brian Le, Alyce Oliver, Evan Manning, Stanley Nahman and Laura Carbone, Medical College of Georgia at Augusta University, Augusta, GA
Background/Purpose: Rheumatoid arthritis (RA) and End Stage Renal Disease (ESRD) are independent risk factors for osteoporotic fractures. Approximately one percent of persons with ESRD have…
Abstract Number: 1633 • 2018 ACR/ARHP Annual Meeting
Fragility Fractures in Psoriatic Arthritis Patients: A Matched-Control Study
Luciano Fernando Lo Giudice¹, Marina Scolnik², Florencia Pierini³, Nicolas Martin Marin Zucaro¹, John Fredy Jaramillo Gallego¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina
Background/Purpose: patients with Psoriatic Arthritis (PsA) in spite of having bone production as one of their characteristic features, very often have osteoporosis, but scarce data…
Abstract Number: 2182 • 2018 ACR/ARHP Annual Meeting
Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data
Ayesha Jaleel¹, Jeffrey R. Curtis², Rui Chen², Huifeng Yun³, Phillip J. Foster⁴, Nicole Wright³, Tarun Arora², Amy S. Mudano², Suzanne Cadarette⁵ and Kenneth Saag², ¹Internal Medicine, Baptist Brookwood Health, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Background/Purpose: Given alendronate’s (ALN) prolonged skeletal retention and emerging safety concerns, the ASBMR task force recommended consideration of a “drug holiday” after 5 years of…
Abstract Number: 2309 • 2018 ACR/ARHP Annual Meeting
Implementation of a Primary Prevention, Population-Based Virtual Osteoporosis Clinic Dramatically Increases the Number of Rural Veterans Receiving Osteoporosis Screening and Treatment
Karla L. Miller¹, Shardool Patel², Grant W. Cannon³ and Zachary L. Anderson², ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center, Salt Lake City, UT, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: The delivery of osteoporosis services is sub-optimal nationally and throughout the Veterans Affairs (VA) healthcare system and particularly poor for rural Veterans. To meet…
Abstract Number: 2319 • 2018 ACR/ARHP Annual Meeting
Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
Patrick Webster¹ and Tarun S. Sharma², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) is an under-recognized and under-treated condition. Many long-term glucocorticoid (GC) users never receive therapy to prevent bone loss or are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].